OptimizeRx Named to Financial Times ―The Americas’ Fastest-Growing Companies List for the Second Consecutive Year
April 13 2021 - 7:51AM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies, physicians, and
patients, has received the ranking of #277 by the Financial Times
(FT) list of The Americas’ Fastest Growing Companies 2021. This
recognition is presented by the FT and Statista Inc., the
world-leading statistics portal and industry ranking provider.
The FT Americas’ Fastest Growing Companies list ranks companies
with the strongest compounded annual revenue growth between 2016
and 2019. OptimizeRx grew more than 46% during that period, showing
its strongest growth to date in 2020 with full year revenue up 76%
year-over-year. Out of the millions of active companies in North
and South America, only the top 500 firms are named to the
list.
“We are thrilled to be part of the FT Americas’ Fastest Growing
Companies ranking, and proud to see our team’s efforts and
continuous drive to innovate being recognized for the second year
in a row by one of the world's most widely read and respected
business publications,” said William Febbo, CEO of OptimizeRx. “Our
platform enhancements over the past year included two critical
point-of-care solutions: the integration of AI-powered real-world
evidence, and the launch of TelaRep™ – a digital solution that
gives prescribers a direct line of communication to the right
pharma contact when they need it.
“We believe both patients and providers deserve access to
actionable and accurate information about prescription medications.
As such, we will continue working on solutions and partnerships to
improve drug affordability, access, and adherence. OptmizeRx’s
offerings are transformational to physician-patient engagement and
define the new modicum of streamlined communications in an
increasingly digital-first world. Additionally, we have only just
started to touch on the many possible ways of assisting the
healthcare industry overcome customer engagement challenges.
Looking ahead, we look forward to making operational progress
through the remainder of the year and expect to continue seeing
record growth,” concluded Mr. Febbo.
About the Financial TimesThe Financial Times
(FT) is one of the world’s leading business news organizations,
recognized internationally for its authority, integrity, and
accuracy. The FT has a paying readership of more than a million
worldwide, three-quarters of which are digital subscriptions. FT is
part of Nikkei Inc., which provides a broad range of information,
news, and services for the global business community. For more
information, visit www.ft.com.
About OptimizeRxOptimizeRx is a digital health
company that provides communications solutions for life science
companies, physicians, and patients. Connecting over half of
healthcare providers in the U.S. and millions of patients through a
proprietary network, the OptimizeRx digital health platform helps
patients afford and stay on medications. The platform unlocks new
patient and physician touchpoints for life science companies along
the patient journey, from point-of-care, to retail pharmacy,
through mobile patient engagement.
For more information, follow the company
on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, and other material
risks.
OptimizeRx Contact Doug Baker, CFOTel
(248) 651-6568 (x807)dbaker@optimizerx.com
Media Relations Contact Maira Alejandra,
Media Relations ManagerTel (754)
245-7070 malejandra@optimizerx.com
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024